Tokyo Tape
Sign in
← Sakai Chemical Industry

Quarterly report · Q2

4078.TEDINET S100S5CT
Period2023-04-01 → 2023-09-30
Filed2023-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥40.5bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥83.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥42.7bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥917m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥3.3bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥885m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥4.6bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥773m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥4.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥2.0bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.9bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥3.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥131.6bnat 2023-09-30Cons.Assets
Total assets¥128.0bnat 2023-03-31Cons.Assets
Total assets¥128.4bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥50.9bnat 2023-09-30Cons.Liabilities
Total liabilities¥43.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥80.7bnat 2023-09-30Cons.Net assets
Net assets / equity¥84.7bnat 2023-03-31Cons.Net assets
Net assets / equity¥85.8bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥15.6bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥12.4bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥15.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.2bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥11.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥773m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥3.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-125.532023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-153.572023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥144.852022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥177.482022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.082022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio60.5%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2023-04-01 → 2023-09-30¥36.8bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2023-04-01 → 2023-09-30¥36.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥498m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.9bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2023-04-01 → 2023-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2023-04-01 → 2023-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥136m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2023-04-01 → 2023-09-30¥144m
—segment totalrevenue2023-04-01 → 2023-09-30¥41.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥40.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥635m
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.0bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2022-04-01 → 2022-09-30¥39.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2022-04-01 → 2022-09-30¥38.6bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥697m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2022-04-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥163m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2022-04-01 → 2022-09-30¥240m
—segment totalrevenue2022-04-01 → 2022-09-30¥43.6bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥42.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥860m
—segment totalsegment profit2022-04-01 → 2022-09-30¥4.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 522
ItemContextValueUnit
Cost of salesPrior1YTDDuration32311000000JPY
Cost of salesCurrentYTDDuration32596000000JPY
Gross profitPrior1YTDDuration10383000000JPY
Gross profitCurrentYTDDuration7875000000JPY
Selling general and administrative expensesPrior1YTDDuration7115000000JPY
Selling general and administrative expensesCurrentYTDDuration6958000000JPY
Operating incomePrior1YTDDuration3267000000JPY
Operating incomeCurrentYTDDuration917000000JPY
Interest income noiPrior1YTDDuration2000000JPY
Interest income noiCurrentYTDDuration4000000JPY
Dividends income noiPrior1YTDDuration90000000JPY
Dividends income noiCurrentYTDDuration78000000JPY
Foreign exchange gains noiPrior1YTDDuration497000000JPY
Foreign exchange gains noiCurrentYTDDuration324000000JPY
Other noiPrior1YTDDuration42000000JPY
Other noiCurrentYTDDuration30000000JPY
Non operating incomePrior1YTDDuration632000000JPY
Non operating incomeCurrentYTDDuration437000000JPY
Interest expenses noePrior1YTDDuration36000000JPY
Interest expenses noeCurrentYTDDuration53000000JPY
Tender offer related expenses noePrior1YTDDuration－JPY
Tender offer related expenses noeCurrentYTDDuration342000000JPY
Other noePrior1YTDDuration33000000JPY
Other noeCurrentYTDDuration73000000JPY
Non operating expensesPrior1YTDDuration69000000JPY
Non operating expensesCurrentYTDDuration469000000JPY
Ordinary incomePrior1YTDDuration3830000000JPY
Ordinary incomeCurrentYTDDuration885000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration1000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration0JPY
Gain on sales of investment securities eiPrior1YTDDuration79000000JPY
Gain on sales of investment securities eiCurrentYTDDuration43000000JPY
Gain on sales of golf memberships eiPrior1YTDDuration1000000JPY
Gain on sales of golf memberships eiCurrentYTDDuration－JPY
Insurance income eiPrior1YTDDuration379000000JPY
Insurance income eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration461000000JPY
Extraordinary incomeCurrentYTDDuration44000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration72000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration98000000JPY
Impairment loss elPrior1YTDDuration－JPY
Impairment loss elCurrentYTDDuration57000000JPY
Other elPrior1YTDDuration0JPY
Other elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration72000000JPY
Extraordinary lossCurrentYTDDuration156000000JPY
Income before income taxesPrior1YTDDuration4218000000JPY
Income before income taxesCurrentYTDDuration773000000JPY
Income taxesPrior1YTDDuration1195000000JPY
Income taxesCurrentYTDDuration2569000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass